SCHEMBL13627962

SCHEMBL13627962

O=C1/C(=N\O)c2ccccc2N1Cc1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
CHRM5 P08912 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GLA P06280 2/20 0.41
GAA P10253 1/20 0.41
ATM Q13315 1/20 0.41
GALR3 O60755 1/20 0.41
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 2/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.39
MEN1 O00255 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160194 0.82 KMT2A (0.53) KMT2ACHRM5KDM4EGLAGAA
SCHEMBL13627876 0.76 CA9 (0.54) CHRM5ATMGALR3MAPTNPSR1
SCHEMBL6606281 0.73 KMT2A (0.54) KMT2AKDM4EGLAGAAATM
SCHEMBL12856311 0.72 ALDH1A1 (0.47) KMT2AGALR3MAPTNPSR1ALDH1A1
SCHEMBL13627878 0.72 ALDH1A1 (0.70) CHRM5GALR3MAPTNPSR1ALDH1A1
SCHEMBL7611051 0.71 ALDH1A1 (0.66) CHRM5MAPTNPSR1ALDH1A1PKM
SCHEMBL7611054 0.71 ALDH1A1 (0.66) CHRM5MAPTNPSR1ALDH1A1PKM
SCHEMBL3779398 0.71 KMT2A (0.52) KMT2AKDM4EGLAGAAATM
SCHEMBL13627881 0.71 CES1 (0.67) CHRM5MAPTNPSR1ALDH1A1PKM
SCHEMBL31268670 0.71 TDP1 (0.48) KMT2AKDM4EGLAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 KMT2A 3594/4885CHRM5 4815/4885KDM4E 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.